Tuesday, 17 June 2014 09:30 – Thursday, 19 June 2014 17:00
Peninsula Square
London
SE10 0DX
United Kingdom
This three day event will discuss three main topics
- Cell Culture Technology Event: Recent advances, future prospect
- Therapeutic proteins and antibodies: from design to function
- Bioprocess development: Discussing facilitation of industrial uptake
With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking.
www.regonline.co.uk/Biopro2014
This event has CPD accreditation
Who Should Attend
All academic and biotechnology/biopharma professionals interested in biological protein and antibody engineering, functional and potency evaluations, biological therapeutics mechanisms of action and translational implications for therapy would find this meeting useful. Individuals interested in the any process that uses complete living cells or their components (e.g., bacteria, enzymes, chloroplasts) to obtain desired products should also attend this event.
The deadline for abstract submissions for oral presentation is April 10th 2014.Abstracts for poster presentation only can be submitted up to two weeks before the event.
You can download the instructions for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf
There will be an open poster session, where posters can be submitted on any subject related to Cells, Proteins and Bioprocessing
Day 1: Cell Culture Technology Event: Recent advances, future prospect
This session will examine some of the latest applications of cell culture technology, some that are still “over the horizon”, and some of the problems that must be solved before it can reach its full potential.
Day 3: Bioprocess development: Discussing facilitation of industrial uptake.
Talks Include:
Micro-cariers: its role in reducing the cost, time, and efforts towards industrial cells proliferation and protein productions
Dr Ali Hilal-Alnaqbi, Assistant Professor UAEU, Visiting Assistant Professor, Harvard, USA
Therapeutic IgE antibodies: enhanced effector functions for cancer therapy
Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King’s College London School of Medicine, UK
Introducing a Novel liquid 3 Dimensional Scaffold for Culturing Cells in 3D
Dr Anthony Mitchell Davies, Director of INCHSA, Dept Clinical Medicine Trinity College Dublin, Ireland
Quantum dot- conjugated antibodies as diagnostic and therapeutic tools for cancer imaging and treatment
Dr Weiming Xu, CEO, London Biotech Ltd, UK
Real time, label-free characterisation of live cells in monolayer culture using high resolution, multi-modal light microscopy
Dr Melissa Mather, Principal Research Fellow, Institute of Biophysics, Imaging and Optical Science, University of Nottingham, UK
Biofabrication technologies for 3D cell culture systems
Dr Lorenzo Moroni, Associate Professor, University of Twente, Tissue Regeneration Department, The Netherlands
Selection of isotype for immunomodulatory anti-cancer antibodies
Dr Ann White, Senior Research Fellow, University of Southampton, UK
3D-tetraculture system mimicking the cellular organization at the alveolar barrier.
Dr Arno C. Gutleb, Chef de projet, Centre de Recherche Public – Gabriel Lippmann, Luxembourg
Additional Speakers Include
- Professor. Fuad Fares, University of Haifa, Israel
- Dr Sergio A. Quezada, Immune Regulation and Tumour Immunotherapy Group, UCL Cancer Institute, UK
- Dr Miriam Dwek, University of Westminster, UK
